US7105574B1
(en)
|
1999-03-26 |
2006-09-12 |
Vical Incorporated |
Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
|
US6936464B1
(en)
|
1992-10-02 |
2005-08-30 |
Cancer Research Technology Limited |
Immune responses to fusion proteins
|
GB9506466D0
(en)
*
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
WO1996006938A1
(de)
*
|
1994-08-26 |
1996-03-07 |
Hoechst Aktiengesellschaft |
Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
|
US6911216B1
(en)
|
1994-10-12 |
2005-06-28 |
Genzyme Corporation |
Targeted delivery via biodegradable polymers
|
ES2264136T3
(es)
*
|
1995-02-21 |
2006-12-16 |
Cantab Pharmaceuticals Research Limited |
Preparaciones virales, vectores, inmunogenos y sus vacunas.
|
US5824485A
(en)
*
|
1995-04-24 |
1998-10-20 |
Chromaxome Corporation |
Methods for generating and screening novel metabolic pathways
|
US6265387B1
(en)
*
|
1995-10-11 |
2001-07-24 |
Mirus, Inc. |
Process of delivering naked DNA into a hepatocyte via bile duct
|
US6537776B1
(en)
|
1999-06-14 |
2003-03-25 |
Diversa Corporation |
Synthetic ligation reassembly in directed evolution
|
US7507722B1
(en)
*
|
1999-11-05 |
2009-03-24 |
Roche Madison Inc. |
Intravascular delivery of nucleic acid
|
US6365344B1
(en)
|
1996-01-23 |
2002-04-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for screening for transdominant effector peptides and RNA molecules
|
AU1707497A
(en)
|
1996-01-23 |
1997-08-20 |
Rigel Pharmaceuticals, Inc. |
Methods for screening for transdominant intracellular effector peptides and rna molecules
|
US5783431A
(en)
*
|
1996-04-24 |
1998-07-21 |
Chromaxome Corporation |
Methods for generating and screening novel metabolic pathways
|
US6242211B1
(en)
|
1996-04-24 |
2001-06-05 |
Terragen Discovery, Inc. |
Methods for generating and screening novel metabolic pathways
|
EP0803573A1
(de)
*
|
1996-04-25 |
1997-10-29 |
Gesellschaft für Biotechnologische Forschung mbH (GBF) |
Polycistronische Expressionskonstrukt mit Cytokinen für multivalente Impstoffe
|
EP0805207A1
(de)
*
|
1996-05-02 |
1997-11-05 |
Gesellschaft für Biotechnologische Forschung mbH (GBF) |
Polycistronische Expressionsplasmid für Tumorabstossungen
|
US20060002959A1
(en)
*
|
1996-11-14 |
2006-01-05 |
Government Of The United States |
Skin-sctive adjuvants for transcutaneous immuization
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US5980898A
(en)
*
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
JP2001512973A
(ja)
*
|
1997-02-24 |
2001-08-28 |
ヘキスト・マリオン・ルセル・インコーポレイテッド |
β−アミロイドのプロセシングの改良されたアッセイ
|
ES2221212T5
(es)
|
1997-10-02 |
2008-12-01 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Metodos para la modulacion de la neovascularizacion y/o el crecimiento de arterias colaterales y/o de otras arterias a partir de conexiones arteriolares preexistentes.
|
US20040258703A1
(en)
*
|
1997-11-14 |
2004-12-23 |
The Government Of The Us, As Represented By The Secretary Of The Army |
Skin-active adjuvants for transcutaneous immunization
|
ATE550042T1
(de)
*
|
1997-11-20 |
2012-04-15 |
Vical Inc |
Behandlung von krebs mithilfe cytokin- exprimierender polynukleotide und zusammensetzungen dafür
|
FR2772047B1
(fr)
|
1997-12-05 |
2004-04-09 |
Ct Nat D Etudes Veterinaires E |
Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
|
US6482406B1
(en)
|
1999-03-26 |
2002-11-19 |
Duncan J. Stewart |
Cell-based gene therapy for the pulmonary system
|
US20030118567A1
(en)
*
|
1999-03-26 |
2003-06-26 |
Stewart Duncan John |
Cell-based therapy for the pulmonary system
|
US9585916B2
(en)
|
1999-03-26 |
2017-03-07 |
Northern Therapeutics Inc. |
Cell based therapy for the pulmonary system
|
CA2266805C
(en)
|
1998-03-27 |
2015-04-28 |
An-Go-Gen Inc. |
Cell-based gene therapy in the treatment of pulmonary disorders
|
US6592623B1
(en)
|
1999-08-31 |
2003-07-15 |
Virginia Commonwealth University Intellectual Property Foundation |
Engineered muscle
|
ATE549032T1
(de)
|
1999-03-26 |
2012-03-15 |
Vical Inc |
Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen
|
JP4932086B2
(ja)
*
|
1999-04-08 |
2012-05-16 |
インターセル ユーエスエイ、インコーポレイテッド |
経皮的免疫のための乾燥製剤
|
US6696424B1
(en)
|
1999-05-28 |
2004-02-24 |
Vical Incorporated |
Cytofectin dimers and methods of use thereof
|
US6943152B1
(en)
*
|
1999-06-10 |
2005-09-13 |
Merial |
DNA vaccine-PCV
|
US6541458B1
(en)
*
|
1999-07-16 |
2003-04-01 |
Merial |
Feline calicivirus genes and vaccines in particular recombinant vaccines
|
WO2001032223A1
(en)
*
|
1999-11-05 |
2001-05-10 |
Mirus Corporation |
Intravascular delivery of nucleic acid
|
ES2170622B1
(es)
*
|
1999-12-03 |
2004-05-16 |
Consejo Superior De Investigaciones Cientificas |
Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
|
EP1240345A2
(de)
*
|
1999-12-10 |
2002-09-18 |
Ariad Gene Therapeutics, Inc. |
Verfahren zur genexpression in primaten
|
US7078388B2
(en)
*
|
2000-01-21 |
2006-07-18 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
US6852705B2
(en)
|
2000-01-21 |
2005-02-08 |
Merial |
DNA vaccines for farm animals, in particular bovines and porcines
|
CA2405525A1
(en)
|
2000-04-12 |
2001-10-25 |
Principia Pharmaceutical Corporation |
Albumin fusion proteins
|
CA2407074A1
(en)
*
|
2000-04-21 |
2001-11-01 |
Jukka Hartikka |
Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
|
US6645745B1
(en)
|
2000-05-30 |
2003-11-11 |
Epidauros Biotechnologie Ag |
Identification of a new member of the cytochrome P450 3A (CYP3A) gene family: CYP3AX
|
US20040204379A1
(en)
*
|
2000-06-19 |
2004-10-14 |
Cheng Seng H. |
Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
|
AU8847801A
(en)
|
2000-08-25 |
2002-03-04 |
Basf Plant Science Gmbh |
Plant polynucleotides encoding novel prenyl proteases
|
AU2001287023A1
(en)
|
2000-09-01 |
2002-03-13 |
Virginia Commonwealth University Intellectual Property Foundation |
Plasma-derived-fibrin-based matrices and tissue
|
EP1366077B1
(de)
|
2000-09-15 |
2011-05-25 |
Coley Pharmaceutical GmbH |
Verfahren zum hochdurchsatzscreening von auf cpg basierenden immunagonisten und -antagonisten
|
US20030074679A1
(en)
*
|
2000-12-12 |
2003-04-17 |
Schwartz Robert J. |
Administration of nucleic acid sequence to female animal to enhance growth in offspring
|
WO2002059142A2
(en)
|
2001-01-26 |
2002-08-01 |
Epidauros Biotechnologies Ag |
Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications
|
AT410634B
(de)
|
2001-02-21 |
2003-06-25 |
Franz X Dr Heinz |
Attenuierte lebendimpfstoffe
|
WO2003015716A2
(en)
*
|
2001-08-13 |
2003-02-27 |
Ige Therapeutics, Inc. |
Immunoglobulin e vaccines and methods of use thereof
|
US20030109037A1
(en)
*
|
2001-09-24 |
2003-06-12 |
Reid Christopher Brian |
Methods for application of genetically-modified endogenous or exogenous stem/progenitor or their progeny for treatment of disease
|
US20080206202A1
(en)
*
|
2001-09-24 |
2008-08-28 |
Christopher Reid |
Methods for application of endogenous or exogenous stem/progenitor or their progeny for treatment of disease
|
US20030157641A1
(en)
*
|
2001-11-16 |
2003-08-21 |
Idec Pharmaceuticals Corporation |
Polycistronic expression of antibodies
|
EP2990417A1
(de)
|
2001-12-21 |
2016-03-02 |
Human Genome Sciences, Inc. |
Albumin-insulin-fusionsprotein
|
AR038568A1
(es)
|
2002-02-20 |
2005-01-19 |
Hoffmann La Roche |
Anticuerpos anti-a beta y su uso
|
DK1355152T3
(da)
|
2002-04-17 |
2010-06-14 |
Deutsches Krebsforsch |
Fremgangsmåde til at identificere en forbindelse til modulering af wnt-signalkaskaden
|
US20060093589A1
(en)
*
|
2004-02-19 |
2006-05-04 |
Warrington Kenneth H |
Vp2-modified raav vector compositions and uses therefor
|
EP1496944B1
(de)
*
|
2002-05-01 |
2008-08-20 |
University of Florida Research Foundation, Inc. |
Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine
|
CA2542171C
(en)
|
2002-06-26 |
2015-12-15 |
Abbott Gmbh & Co. Kg |
Modulators and modulation of the interaction between rgm and neogenin
|
US6809191B2
(en)
*
|
2002-07-03 |
2004-10-26 |
Vaxim, Inc. |
GM-CSF nucleic acid sequences
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
WO2004055157A2
(en)
*
|
2002-08-13 |
2004-07-01 |
Whitley Chester B |
Methods of using vectors to treat metabolic disorders
|
EP1530628B1
(de)
|
2002-08-16 |
2010-09-29 |
Glycotope GmbH |
Verfahren zur herstellung von temperaturinduzierten tumorzell-lysaten zur verwendung als immunogene verbindungen
|
AU2003264094A1
(en)
|
2002-08-23 |
2004-03-11 |
Epidauros Biotechnologie Ag |
Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
|
US20070225631A1
(en)
*
|
2002-10-04 |
2007-09-27 |
Bowlin Gary L |
Sealants for Skin and Other Tissues
|
WO2004060346A2
(en)
|
2002-12-30 |
2004-07-22 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
US20040136960A1
(en)
*
|
2003-01-10 |
2004-07-15 |
Wolff Jon A. |
Devices and processes for distribution of genetic material to mammalian limb
|
CA2532228C
(en)
|
2003-07-16 |
2017-02-14 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
WO2005017130A2
(en)
|
2003-08-18 |
2005-02-24 |
Glycotope Gmbh |
Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses thereof
|
SI2157192T1
(sl)
|
2003-10-10 |
2013-11-29 |
Deutsches Krebsforschungszentrum |
Sestavki za diagnozo in terapijo bolezni, povezanih z aberantno ekspresijo Futrinov (R-Spondinov)
|
SI1673398T1
(sl)
|
2003-10-16 |
2011-05-31 |
Micromet Ag |
Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule
|
EP1706423B8
(de)
|
2003-12-05 |
2009-07-08 |
multimmune GmbH |
Therapeutische und diagnostische anti-hsp 70-antikörper
|
AU2005210151B2
(en)
|
2004-02-09 |
2010-07-01 |
Aigner, Ludwig Dr. |
Inhibitors of TGF-R signaling for treatment of CNS disorders
|
US7504243B2
(en)
|
2004-03-19 |
2009-03-17 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods for the production of biliverdin
|
EP1761784B1
(de)
|
2004-05-24 |
2016-10-26 |
Universität Zu Köln |
Identifizierung des ergothionein-transporters und therapeutische verwendungen davon
|
EP1602926A1
(de)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
|
DK2229956T3
(da)
|
2004-09-13 |
2013-07-29 |
Genzyme Corp |
Multimere konstruktioner
|
EP2314308A1
(de)
|
2004-09-21 |
2011-04-27 |
BioNTech AG |
Verwendung von Mikroproteinen als Tryptase Inhibitoren
|
EP1877087B1
(de)
|
2005-04-15 |
2013-02-20 |
GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Verfahren und zusammensetzungen zur erzeugung einer verbesserten immunantwort auf ein menschliches papillomavirus-immunogen
|
US8048446B2
(en)
*
|
2005-05-10 |
2011-11-01 |
Drexel University |
Electrospun blends of natural and synthetic polymer fibers as tissue engineering scaffolds
|
MX363423B
(es)
|
2005-05-18 |
2019-03-22 |
Ablynx Nv |
Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
|
CN101213214B
(zh)
|
2005-05-20 |
2014-06-25 |
埃博灵克斯股份有限公司 |
针对冯威勒布兰特因子的单一结构域vhh抗体
|
CN101277974A
(zh)
|
2005-09-30 |
2008-10-01 |
阿伯特有限及两合公司 |
排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
|
CA2566267A1
(en)
*
|
2005-12-09 |
2007-06-09 |
University Health Network |
Thymidylate kinase mutants and uses thereof
|
US20090068158A1
(en)
*
|
2005-12-09 |
2009-03-12 |
Medin Jeffrey A |
Thymidylate kinase mutants and uses thereof
|
ZA200805400B
(en)
|
2005-12-21 |
2009-09-30 |
Micromet Ag |
Pharmaceutical compositions with resistance to soluble CEA
|
WO2007098607A1
(en)
|
2006-03-03 |
2007-09-07 |
Amorfix Life Sciences Ltd. |
Methods and compositions to treat and detect misfolded-sod1 mediated diseases
|
CA2655990A1
(en)
|
2006-06-22 |
2007-12-27 |
Tai June Yoo |
Restoration of hearing loss
|
KR101603632B1
(ko)
|
2006-09-10 |
2016-03-16 |
글리코토페 게엠베하 |
항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도
|
PL1920781T3
(pl)
|
2006-11-10 |
2015-06-30 |
Glycotope Gmbh |
Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
|
US20100062004A1
(en)
|
2006-12-19 |
2010-03-11 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
AU2007336243B2
(en)
|
2006-12-19 |
2012-07-26 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
|
CA2712056C
(en)
|
2007-01-16 |
2016-06-21 |
The University Of Queensland |
Method of inducing an immune response
|
NZ579050A
(en)
|
2007-02-06 |
2012-10-26 |
Tai June Yoo |
Treatment and prevention of neurodegenerative diseases using gene therapy
|
CA2584494A1
(en)
*
|
2007-03-27 |
2008-09-27 |
Jeffrey A. Medin |
Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
|
WO2008119565A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific binding domain
|
RS58217B1
(sr)
|
2007-04-03 |
2019-03-29 |
Amgen Res Munich Gmbh |
Interspecijski specifičan vezujući domen
|
US8895002B2
(en)
|
2007-04-09 |
2014-11-25 |
The General Hospital Corporation |
Hemojuvelin fusion proteins and uses thereof
|
MX2009011851A
(es)
|
2007-05-02 |
2010-03-04 |
Merial Ltd |
Plasmidos de dna que tienen expresion y estabilidad mejoradas.
|
WO2008135237A1
(en)
|
2007-05-03 |
2008-11-13 |
Medizinische Universität Innsbruck |
Complement factor h-derived short consensus repeat-antibody constructs
|
EP2150618B1
(de)
|
2007-05-04 |
2017-10-11 |
University Health Network |
Il-12-immuntherapie gegen krebs
|
CA2688346A1
(en)
|
2007-05-23 |
2008-12-04 |
Vical Incorporated |
Compositions and methods for enhancing immune responses to vaccines
|
SG10201903161XA
(en)
|
2007-05-29 |
2019-05-30 |
Christopher Reid |
Methods for production and uses of multipotent cell populations
|
JP2011510647A
(ja)
|
2008-01-29 |
2011-04-07 |
プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ |
遺伝子発現の転写後抑制を相乗的に生じさせることができる方法および組成物
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
WO2009114942A1
(en)
|
2008-03-20 |
2009-09-24 |
University Health Network |
Thymidylate kinase fusions and uses thereof
|
CA2720763A1
(en)
|
2008-04-07 |
2009-10-15 |
Ablynx Nv |
Amino acid sequences directed against the notch pathways and uses thereof
|
WO2009137829A2
(en)
|
2008-05-09 |
2009-11-12 |
Wake Forest University Health Sciences |
Directed stem cell recruitment
|
WO2010037838A2
(en)
|
2008-10-01 |
2010-04-08 |
Micromet Ag |
Cross-species-specific single domain bispecific single chain antibody
|
PT2356153T
(pt)
|
2008-10-01 |
2016-07-15 |
Amgen Res (Munich) Gmbh |
Anticorpo biespecífico, de cadeia única, amepxcd3, específico interespécies
|
MX2011005851A
(es)
|
2008-12-04 |
2011-07-29 |
Opko Opthalmics Llc |
Composiciones y metodos para la inhibicion selectiva de isoformas vegf proangiogenicas.
|
CN104922676B
(zh)
|
2009-03-20 |
2019-03-12 |
Clsn实验室股份有限公司 |
聚胺衍生物
|
RU2539798C2
(ru)
|
2009-04-10 |
2015-01-27 |
Аблинкс Нв |
Улучшенные аминокислотные последовательности против il-6r и содержащие их полипептиды для лечения связанных с il-6r заболеваний и нарушений
|
CA2764398A1
(en)
|
2009-06-05 |
2010-12-09 |
Erik Depla |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
JP5897464B2
(ja)
*
|
2009-08-07 |
2016-03-30 |
トランジェーヌ、ソシエテ、アノニムTransgene S.A. |
Hbv感染を治療するための組成物
|
WO2011062962A2
(en)
|
2009-11-17 |
2011-05-26 |
The Trustees Of The University Of Pennsylvania |
Smndelta7 degron: novel compositions and methods of use
|
EP2507262A1
(de)
|
2009-11-30 |
2012-10-10 |
Ablynx N.V. |
Verbesserte gegen hrsv gerichtete aminosäuresequenzen und polypeptide damit zur prävention und/oder behandlung von atemwegsinfektionen
|
ES2562832T3
(es)
|
2009-12-08 |
2016-03-08 |
Abbvie Deutschland Gmbh & Co Kg |
Anticuerpos monoclonales contra la proteína RGM para su uso en el tratamiento de la degeneración de la capa de fibra nerviosa de la retina
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
跨物種專一性之PSMAxCD3雙專一性單鏈抗體
|
SI2585477T1
(sl)
|
2010-06-23 |
2019-03-29 |
Deutsches Krebsforschungszentrum |
Preurejene tt virusne molekule za uporabo v diagnozi, preprečevanje in zdravljenje raka in avtoimunosti
|
ES2657705T3
(es)
|
2010-06-23 |
2018-03-06 |
Deutsches Krebsforschungszentrum |
Secuencias de virus TT específicas y moléculas de ADN quiméricas de células hospedadoras de virus TT para uso en el diagnóstico, prevención y tratamiento del cáncer y la autoinmunidad
|
EP2481801A1
(de)
|
2011-01-28 |
2012-08-01 |
Deutsches Krebsforschungszentrum |
Inhibitoren von verzweigtkettiger Aminotransferase-1 (BCAT1) zur Behandlung von Neoplasie
|
WO2012149047A1
(en)
|
2011-04-29 |
2012-11-01 |
Sequenom, Inc. |
Multimer glycosylated nucleic acid binding protein conjugates and uses thereof
|
ES2560604T3
(es)
|
2011-06-09 |
2016-02-22 |
Deutsches Krebsforschungszentrum |
Moduladores de glicerol-3-fosfato deshidrogenasa (GPD2) para terapia
|
WO2013006841A1
(en)
|
2011-07-06 |
2013-01-10 |
Yale University |
Stimulation of arterial collateral growth and lymphogenesis
|
DE202011103324U1
(de)
|
2011-07-12 |
2012-01-02 |
Nekonal S.A.R.L. |
Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
|
CN103814123A
(zh)
|
2011-08-22 |
2014-05-21 |
葛莱高托普有限公司 |
携带肿瘤抗原的微生物
|
US20130071403A1
(en)
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
DK2807192T3
(en)
|
2012-01-27 |
2018-07-23 |
Abbvie Deutschland |
COMPOSITION AND PROCEDURE FOR DIAGNOSTICATION AND TREATMENT OF DISEASES RELATED TO NEURITE DEGENERATION
|
BR112014019116B1
(pt)
|
2012-02-03 |
2024-01-23 |
F.Hoffmann-La Roche Ag |
Kit, moléculas de anticorpo e uso de uma molécula de anticorpo
|
EP2657340B1
(de)
|
2012-04-25 |
2016-11-16 |
Deutsches Krebsforschungszentrum |
Hemmer von mit Thioredoxin interagierendem Protein (TXNIP) zur Therapie
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
US10028998B2
(en)
|
2012-10-30 |
2018-07-24 |
Suppremol Gmbh |
Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
|
EP2920319B1
(de)
|
2012-11-16 |
2020-02-19 |
Poseida Therapeutics, Inc. |
Ortsspezifische enzyme und verfahren zur verwendung
|
WO2014145205A2
(en)
|
2013-03-15 |
2014-09-18 |
St. Jude Children's Research Hospital |
Methods and compositions of p27kip1 transcription modulators
|
EP3339318A1
(de)
|
2013-09-16 |
2018-06-27 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Mutiertes calreticulin zur diagnose von myeloidmalignitäten
|
RU2662685C2
(ru)
|
2013-09-25 |
2018-07-26 |
Зоэтис Сервисиз Ллс |
Pcv2b дивергентная вакцинная композиция и способы её применения
|
EP2868751A1
(de)
|
2013-10-30 |
2015-05-06 |
Deutsches Krebsforschungszentrum |
HCBI-Sequenzen als früher Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des zentralen Nervensystems, und als Ziel zur Behandlung und Prävention von Krebs
|
EP2937096B1
(de)
|
2014-04-23 |
2019-08-21 |
Julius-Maximilians-Universität Würzburg |
Aus RS1 abgeleitete Peptide, die Glukoseabsorption nach einer glukosereichen Mahlzeit herunterregulieren und die Insulinsensitivität steigern
|
US20170073690A1
(en)
|
2014-05-15 |
2017-03-16 |
CEMM - Forschungzentrum Fuer Molekulare Medizin GMBH |
Antagonists of slc38a9 and their use in therapy
|
EP2966176A1
(de)
|
2014-07-10 |
2016-01-13 |
Deutsches Krebsforschungszentrum |
HCBIO-, MSBI-, MSSI- und CMI-Sequenzen als frühe Marker für die zukünftige Entwicklung von Krebs und Erkrankungen des ZNS und als Ziel zur Behandlung und Prävention dieser Erkrankungen
|
BR112017017825A2
(pt)
|
2015-02-23 |
2018-04-10 |
Seagull Therapeutics Sas |
semaforinas 3 não naturais e seu uso médico
|
PT3310909T
(pt)
|
2015-06-17 |
2021-09-09 |
Poseida Therapeutics Inc |
Composições e métodos para dirigir proteínas para loci específicos no genoma
|
US20180161340A1
(en)
|
2015-06-18 |
2018-06-14 |
St. Jude Children's Research Hospital |
Methods and compositions for the prevention and treatment of hearing loss
|
BR112018012784A2
(pt)
|
2015-12-22 |
2019-02-05 |
Univ Muenchen Tech |
ácidos nucleicos que codificam as sequências de aminoácido repetitivas ricas em resíduos de prolina e alanina que possuem sequências de nucleotídeo de baixa repetição
|
EP3216458A1
(de)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modifizierter vaskulärer endothelialen wachstumsfaktor a (vegf-a) und dessen medizinische verwendung
|
US10036024B2
(en)
|
2016-06-03 |
2018-07-31 |
Purdue Research Foundation |
siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
|
CA3026858A1
(en)
|
2016-06-30 |
2018-01-04 |
F. Hoffmann-La Roche Ag |
Improved adoptive t-cell therapy
|
WO2018177966A1
(en)
|
2017-03-27 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Improved antigen binding receptors
|
BR112019017629A2
(pt)
|
2017-03-27 |
2020-04-07 |
Hoffmann La Roche |
receptor de união ao antígeno, polinucleotídeo isolado, vetor, célula t transduzida, métodos para o tratamento de uma doença e para induzir a lise, utilização do receptor e receptor
|
WO2019126578A1
(en)
|
2017-12-20 |
2019-06-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for directing proteins to specific loci in the genome
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
EP4257611A3
(de)
|
2018-05-18 |
2024-03-06 |
Glycotope GmbH |
Anti-muc1-antikörper
|
EP3686289A1
(de)
|
2019-01-24 |
2020-07-29 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Cmi-sequenzen als frühmarker für die zukünftige entwicklung von krebs, atherosklerose, diabetes und erkrankungen des zns und als ziel für die behandlung und prävention dieser erkrankungen
|
KR20230042292A
(ko)
|
2020-08-03 |
2023-03-28 |
에프. 호프만-라 로슈 아게 |
개선된 항원 결합 수용체
|
CN116507640A
(zh)
|
2020-10-28 |
2023-07-28 |
豪夫迈·罗氏有限公司 |
改善的抗原结合受体
|
MX2023006604A
(es)
|
2020-12-04 |
2023-06-19 |
Tidal Therapeutics Inc |
Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos.
|
WO2022157548A1
(en)
|
2021-01-24 |
2022-07-28 |
Forrest Michael David |
Inhibitors of atp synthase - cosmetic and therapeutic uses
|
EP4373859A1
(de)
|
2021-07-22 |
2024-05-29 |
F. Hoffmann-La Roche AG |
Heterodimere fc-domänen-antikörper
|
EP4436995A1
(de)
|
2021-11-25 |
2024-10-02 |
F. Hoffmann-La Roche AG |
Verbesserte antigenbindende rezeptoren
|
WO2023180511A1
(en)
|
2022-03-25 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Improved chimeric receptors
|
TW202423482A
(zh)
|
2022-06-08 |
2024-06-16 |
美商泰德治療公司 |
可電離陽離子脂質和脂質奈米顆粒、及其合成方法和用途
|